Colon Cancer

Oncology
14
Pipeline Programs
15
Companies
20
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
8
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
457%
Small Molecule
343%
+ 13 programs with unclassified modality

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
2 programs
1
1
QL1706Phase 31 trial
CapecitabinePhase 11 trial
Active Trials
NCT03435666UnknownEst. Nov 2018
NCT06686576RecruitingEst. Dec 2030
Pfizer
PfizerNEW YORK, NY
1 program
1
IsovorinPhase 31 trial
Active Trials
NCT00195585Completed650Est. Feb 2006
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
3
PanitumumabPhase 2Monoclonal Antibody1 trial
PanitumumabPhase 2Monoclonal Antibody1 trial
PanitumumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00819780Completed285Est. Jul 2016
NCT00411450Completed116Est. Oct 2010
NCT03442569Completed56Est. Dec 2024
Regeneron
RegeneronTARRYTOWN, NY
2 programs
2
CemiplimabPhase 2Monoclonal Antibody1 trial
Cemiplimab + Fianlimab [Fixed Dose CombinationPhase 21 trial
Active Trials
NCT05961709Recruiting50Est. Apr 2028
NCT07224022Not Yet Recruiting24Est. Jul 2029
M&
Merck & Co.RAHWAY, NJ
1 program
1
Perioperative simplified FOLFOX-4 chemotherapyPhase 21 trial
Active Trials
NCT01675999Unknown186Est. Feb 2021
Bayer
BayerLEVERKUSEN, Germany
1 program
1
RegorafenibPhase 2Small Molecule1 trial
Active Trials
NCT02402036Terminated10Est. Nov 2017
Takeda
TakedaTOKYO, Japan
1 program
1
fruquintinibPhase 2Small Molecule1 trial
Active Trials
NCT07011576Recruiting60Est. Jun 2027
Novartis
NovartisBASEL, Switzerland
1 program
1
EPO906, celecoxibPhase 1/2Small Molecule1 trial
Active Trials
NCT00159484Unknown75Est. Dec 2017
E
EisaiChina - Liaoning
1 program
1
FOLFIRIPhase 1/21 trial
Active Trials
NCT01347645Terminated82Est. Jun 2015
Sapience Therapeutics
Sapience TherapeuticsNY - Tarrytown
1 program
1
ST316Phase 11 trial
Active Trials
NCT05848739RecruitingEst. May 2027
Alliance Pharmaceuticals
2 programs
Non-interventionalN/A1 trial
Quality of Life Ted TalksN/A1 trial
Active Trials
NCT03951389Completed750Est. Oct 2019
NCT04713007Active Not Recruiting60Est. Feb 2026
EXACT Therapeutics
EXACT TherapeuticsNorway - Oslo
1 program
CologuardN/A1 trial
Active Trials
NCT04124406Active Not Recruiting150,000Est. Dec 2025
Cosmo Pharmaceuticals
Cosmo PharmaceuticalsIreland - Dublin
1 program
ColonoscopyN/A1 trial
Active Trials
NCT06216405CompletedEst. Jan 2024
Genomics
GenomicsUK - Oxford
1 program
Plasma ctDNA in Patients Undergoing Diagnostic ColonoscopyN/A1 trial
Active Trials
NCT02665299Completed206Est. Aug 2017
Olympus
OlympusPA - Center Valley
1 program
THUNDERBEATN/A1 trial
Active Trials
NCT02628093Completed73Est. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Qilu PharmaceuticalQL1706
PfizerIsovorin
RegeneronCemiplimab + Fianlimab [Fixed Dose Combination
Takedafruquintinib
RegeneronCemiplimab
AmgenPanitumumab
BayerRegorafenib
Merck & Co.Perioperative simplified FOLFOX-4 chemotherapy
AmgenPanitumumab
AmgenPanitumumab
EisaiFOLFIRI
NovartisEPO906, celecoxib
Sapience TherapeuticsST316
Qilu PharmaceuticalCapecitabine
Cosmo PharmaceuticalsColonoscopy

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 152,683 patients across 20 trials

NCT06686576Qilu PharmaceuticalQL1706

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Start: Dec 2024Est. completion: Dec 2030
Phase 3Recruiting
NCT00195585PfizerIsovorin

Study Evaluating Isovorin in Colon Cancer

Start: Oct 2002Est. completion: Feb 2006650 patients
Phase 3Completed
NCT07224022RegeneronCemiplimab + Fianlimab [Fixed Dose Combination

Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer

Start: Feb 2026Est. completion: Jul 202924 patients
Phase 2Not Yet Recruiting
NCT07011576Takedafruquintinib

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Start: Sep 2025Est. completion: Jun 202760 patients
Phase 2Recruiting
NCT05961709RegeneronCemiplimab

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Start: May 2024Est. completion: Apr 202850 patients
Phase 2Recruiting
NCT03442569AmgenPanitumumab

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Start: Mar 2018Est. completion: Dec 202456 patients
Phase 2Completed
NCT02402036BayerRegorafenib

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

Start: Feb 2015Est. completion: Nov 201710 patients
Phase 2Terminated
NCT01675999Merck & Co.Perioperative simplified FOLFOX-4 chemotherapy

Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer

Start: May 2012Est. completion: Feb 2021186 patients
Phase 2Unknown
NCT00819780AmgenPanitumumab

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Start: Apr 2009Est. completion: Jul 2016285 patients
Phase 2Completed
NCT00411450AmgenPanitumumab

Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment

Start: Nov 2006Est. completion: Oct 2010116 patients
Phase 2Completed
NCT01347645EisaiFOLFIRI

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Start: Sep 2011Est. completion: Jun 201582 patients
Phase 1/2Terminated
NCT00159484NovartisEPO906, celecoxib

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

Start: Oct 2004Est. completion: Dec 201775 patients
Phase 1/2Unknown
NCT05848739Sapience TherapeuticsST316

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Start: Jun 2023Est. completion: May 2027
Phase 1Recruiting
NCT03435666Qilu PharmaceuticalCapecitabine

A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition

Start: May 2018Est. completion: Nov 2018
Phase 1Unknown
NCT06216405Cosmo PharmaceuticalsColonoscopy

Performance of Artificial Intelligence in Colonoscopy for Right Colon Polyp Detection

Start: Jan 2022Est. completion: Jan 2024
N/ACompleted
NCT04713007Alliance PharmaceuticalsQuality of Life Ted Talks

Improving Quality of Life for Colon Cancer Patients and Their Caregivers

Start: Jun 2021Est. completion: Feb 202660 patients
N/AActive Not Recruiting
NCT04124406EXACT TherapeuticsCologuard

Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality

Start: Oct 2019Est. completion: Dec 2025150,000 patients
N/AActive Not Recruiting
NCT02628093OlympusTHUNDERBEAT

A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery

Start: Feb 2016Est. completion: May 201973 patients
N/ACompleted
NCT02665299GenomicsPlasma ctDNA in Patients Undergoing Diagnostic Colonoscopy

Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy

Start: Jan 2016Est. completion: Aug 2017206 patients
N/ACompleted
NCT03951389Alliance PharmaceuticalsNon-interventional

INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer

Start: May 2012Est. completion: Oct 2019750 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
6h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 152,683 patients
15 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)